The initial version of the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) framework introduced a 4-point PSMA-expression score to describe the PSMA-expression of primary tumours and metastases, aiming to standardize the interpretation and reporting of PSMA-targeted imaging studies [5]. This evidence concerns the gene FOLH1 and prostate carcinoma.